This inventor holds 1 USPTO granted patent. Top assignee: Nanjing China-Australia Institute of Translational Medicine Co. Ltd.. Active years: 2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2023
Title: Innovations of Quan Zhao in Lung Cancer Treatment.
Introduction
Quan Zhao is a notable inventor based in Jiangsu, China. He has made significant contributions to the field of medicine, particularly in the treatment of non-small cell lung cancer. His innovative approach involves the use of small-molecule inhibitors, which have the potential to improve patient outcomes.
Latest Patents
Quan Zhao holds a patent for the use of AURKB small-molecule inhibitors for the treatment of non-small cell lung cancer. This patent discloses the use of a small-molecule AURKB inhibitor directed to a diindolylmethane compound, which can be a solvate, a N-oxide, or a pharmaceutically acceptable salt thereof. This innovative treatment method represents a promising advancement in cancer therapy.
Career Highlights
Zhao is associated with the Nanjing China-Australia Institute of Translational Medicine Co. Ltd., where he continues to work on groundbreaking research. His dedication to developing effective treatments for cancer showcases his commitment to improving healthcare.
Collaborations
He collaborates with esteemed colleagues such as Renxiang Tan and Yadong Wang, contributing to a dynamic research environment that fosters innovation and discovery.
Conclusion
Quan Zhao's work in developing small-molecule inhibitors for lung cancer treatment exemplifies the impact of innovative research in medicine. His contributions are paving the way for new therapeutic options in oncology.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile